PFIZER INC.

Peter Marks, former director of the FDA's Center for Biologics Evaluation and Research, has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease work.

Valneva secured a $500 million debt facility with Pharmakon Advisors, extending repayment from Q1 2026 to Q4 2030 with improved financial terms.

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.

The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.

TAHO Pharmaceuticals has submitted a New Drug Application to the FDA for TAH3311, the world's first apixaban oral dissolving film designed for patients with swallowing difficulties.

Researchers at Moffitt Cancer Center demonstrated that combining avelumab immunotherapy with whole brain radiotherapy showed promising safety and efficacy in treating leptomeningeal disease, a devastating cancer complication.

Indivior has discontinued marketing of Opvee, its controversial overdose-reversal medication, following a settlement with New York Attorney General Letitia James after two years of poor sales and intense scrutiny.

The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.

Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.

MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.